A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation.

Trial Profile

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs GI 4000 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Sponsors GlobeImmune
  • Most Recent Events

    • 28 Jan 2014 As per the Clinicaltrials.gov record, status changed from active, no longer recruiting to completed.
    • 14 Sep 2011 Planned end date changed from 1 Dec 2010 to 1 Jul 2012 according to ClinicalTrials.gov.
    • 01 Jun 2011 Results presented in ASCO-2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top